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Analysis of clinical and dosimetric factors associated with severe 
radiation pneumonitis in locally advanced Non-Small-Cell-Lung-
Cancer patients treated with concurrent chemotherapy and 
intensity-modulated radiotherapy (IMRT)
Shi, Anhui; Zhu, Guangying; Yu, Rong; Li, Fuhai; Li, Dongming; Sun, 
Yan; Xu, Bo 
Department of Radiation Oncology, Cancer Hospital, School of Oncol-
ogy, Peking University, Beijing, China
Purpose: To retrospectively evaluate clinical and dosimetric factors 
associated with severe (grade≥3) radiation pneumonitis in patients 
after concurrent chemotherapy and intensity-modulated radiotherapy 
(IMRT).
Methods: We retrospectively analyzed 94 locally advanced NSCLC 
patients treated with concurrent chemotherapy and IMRT between 
May 2005 and September 2006. Radiation pneumonitis was graded 
according to Common Terminology Criteria for Adverse Events version 
3.0. The following clinical parameters were considered: gender, age, 
smoking and diabetes history, history of chronic obstructive pulmonary 
disease (COPD), induction chemotherapy, concurrent chemotherapy 
regimens, performance status and forced expiratory volume in 1 second 
(FEV1). Dosimetric factors including mean lung dose (Dmean), rV5-
V60 relative volumes of lung receiving more than a threshold dose D 
of radiation (rVD), where values of D considered were 5˚C 60 Gy in 
increments of 5 Gy), prescribed dose (63GY/35f/7w vs 60Gy/30f/6w), 
and normal tissue complication probability (NTCP) values were 
analysed. DVHs data and NTCP values were collected for both lungs 
considered as a parallel organ. Pearson Chi-Square test was performed 
to compare clinical parameters between patients who developed severe 
RP and those who did not. Univariate and multivariate logistic regres-
sion analyses were performed to evaluate data for association between 
clinical and dosimetric factors and severe RP. The study was approved 
by the institutional reviewboard. 
Results: Of 94 patients, 11 (11.7%) develop severe (grade≥3) radiation 
pneumonitis; 6 (6.4%), grade 3; 2(2.1%), grade 4; and 3 (3.2%)grade 
5. Univariate analyses show that Sex, age (≤60vs>60), smoking and 
diabetes history, induction chemotherapy, concurrent chemotherapy 
regimens, PS(≤70vs>70) and prescribed dose did not signiﬁcantly dif-
fer between patients who developed severe RP and those who did not. 
However, NTCP, MLD, rV5-V60, COPD and FEV1 were associated 
with severe RP (p<0.05). In multivariate analysis, NTCP (p=0.001) and 
rV10(p=0.015) was the most signiﬁcant factors associated with severe 
(grade≥3) radiation pneumonitis. The incidences of Grade≥3 pneumo-
nitis in the group with NTCP>4.2% and NTCP <4.2% were 43.5% and 
1.4%, respectively (p<0.01). The incidences of Grade≥3 pneumonitis in 
the group with rV10 <51.2% and rV10 >51.2% were 5.6% and 30.4%, 
respectively (p<0.01).
Conclusions: NTCP and rV10 is useful indicator of risk for develop-
ment of severe (grade≥3) radiation pneumonitis in NSCLC patients 
after concurrent chemotherapy and intensity -modulated radiotherapy 
(IMRT).
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A multicenter phase II randomized study of paclitaxel (P) and 
carboplatin (C) versus oral vinorelbine (oV) and carboplatin (C) as 
second-line treatment in patients with non-small cell lung cancer 
(NSCLC) pretreated with non-platinum based chemotherapy
Agelidou, A.1 Agelaki, S.2 Chandrinos, V.1 Polyzos, A.1 Agelidou, 
M.1 Papakotoulas, P.1 Kentepozidis, N.1 Giassas, S.1 Kalbakis, K.2 
Georgoulias, V.2 
1 Hellenic Oncology Research Group, Athens, Greece 2 Hellenic Oncol-
ogy Research Group, Heraklion, Greece 
Background: Limited data is available on the activity of platinum-
containing doublets as second-line treatment of NSCLC patients who 
received non-patinum based ﬁrst-line therapy. We performed a multi-
center randomized phase II trial to compare PC and oVC in NSCLC 
patients (pts) pretreated with ﬁrst-line docetaxel (D)/gemcitabine (G).
Methods: Pts with stage IIIB/IV NSCLC and adequate performance 
status (PS), haematological, hepatic, cardiac and renal function pre-
treated with DG were eligible. Pts received P 140 mg/m2 combined 
with C AUC3 or oV 45 mg/m2 combined with C AUC3 on days 1 and 
15 of a 30-day cycle. Stratiﬁcation was done for PS and response to 
prior treatment. Primary endpoint was response rate (RR) and second-
ary endpoints were time to progression (TTP), survival and toxicity. 
Results: 140 pts were randomized to PC (n= 65) or oVG (n= 75). 
Median age was 60 yrs for both arms (range, 39-74 and 38-79, respec-
tively) and PS was 0-1 in 91% and 85%, for PC and oVC, respectively. 
In an intension-to-treat analysis, signiﬁcantly more responders were ob-
served in the PC arm with an overall RR of 19.4% vs 4.2% (p=0.006). 
After a median follow up time of 5.4 (range 0.5-30) months, median 
TTP was 3.2 (range, 0.5-23.7) vs 2.8 (range, 0.5-18.5) for PC and 
oVC, respectively (p=0.150). Median overall survival was 6.3 (range, 
0.5–26.2) vs 6.1 (range, 0.5–30) months and 1-yr survival was 29.4% 
vs 27.5% for PC and oVC, respectively (p=0.586). The two arms ex-
hibited similar rates of grade 3 and 4 toxicity. 
Conclusions: A higher response rate that was not translated to a sur-
vival beneﬁt was recorded for the PC arm. No signiﬁcant differences in 
toxicity rates were observed. 
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A phase II trial of weekly cisplatin and docetaxel in advanced non-
small cell lung cancer (NSCLC)
Sovak, Mika A. Lutzker, Stuart Guensch, Lisa Joyce, Margaret 
Schwartz, Susan Wu, Yujun Zheng, Ling Aisner, Joseph 
The Cancer Institute of New Jersey, New Brunswick, NJ, USA
Background: Every 3-week cisplatin doublets used to treat advanced 
NSCLC carry a signiﬁcant risk of renal and other toxicities and can 
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be difﬁcult for patients with co-morbidities. To reduce these toxicities, 
we conducted a phase II study to evaluate the efﬁcacy and toxicity of 
weekly cisplatin and docetaxel in advanced NSCLC.
Methods: Eligibility included patients with advanced or recurrent 
NSCLC, ECOG PS of 0-1, and no prior chemotherapy for metastatic 
disease. This Cancer Institute of New Jersey network, single stage 
phase II clinical trial was designed to give 3 weekly doses of cisplatin 
at 25 mg/m2 and docetaxel at 35 mg/m2, followed by 1 week of rest, 
for a total of 6 cycles of therapy. Toxicity was monitored weekly, and 
disease evaluation was performed every 2 cycles. The primary endpoint 
was response rate (RR); secondary endpoints included time to progres-
sion (TTP), median and 1-year survival. 
Results: From 12/03 to 03/07, 38 patients were enrolled so far. The 
median age of patients is 63 (range 47-78), the majority is white 
(n=35), 31 have stage IV disease, and almost half (n=18) are women. 
Fifteen have an ECOG PS=0 and 23 with PS=1. Histologic subtypes 
are: adenocarcinoma (n=26), NSCLC NOS (n=7), squamous (n=5). 
Fourteen patients received ? 4 cycles of therapy; median number of 
cycles delivered is 2.4. Reasons for treatment discontinuation include 
completion of therapy (n=7), progression of disease (n=17), adverse 
events (n=8), and patient preference (n=4). Two patients continue on 
therapy at this time. No complete responses were yet observed; 8 pa-
tients (21%) achieved a partial response; 10 patients had stable disease, 
10 patients progressed, 8 came off study before ﬁrst disease evaluation, 
and 2 have not yet had disease evaluation. Median TTP was 3.8 months 
(mo) (95% CI 2.0, 4.7), median survival is 8.7 mo (95% CI 5.6,16.2) 
and 1-year survival is 40.2% (95% CI 20.9, 58.8). Most toxicities 
were mild but also included neutropenia (grade 3, n=1; grade 4, n=1), 
neutropenic fever (n=1), renal toxicity (grade 3, n=2), nausea (grade 
3, n=1), fatigue (grade 3, n=3), diarrhea (grade 3, n=4) and metabolic 
abnormalities (grade 3, n=3). 
Conclusion: Weekly cisplatin and docetaxel is well tolerated with a 
low incidence of toxicity and demonstrates activity similar to every 
3-week treatment in patients with advanced NSCLC.
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The Portuguese experience with pemetrexed (ALIMTA) in second 
line treatment of non-small cell lung cancer
Araujo, António M.1 Barata, Fernando2 Parente, Bárbara3 Rego, Sónia1 
Teixeira, Encarnação4 Melo, Maria J.5 Queiroga, Henrique6 Cunha, 
João7 Duarte, José8 
1 Portuguese Institute of Oncology - Porto Centre, Porto, Portugal 2 
Centro Hospitalar de Coimbra, Coimbra, Portugal 3 Centro Hospi-
talar V. N. Gaia, V. N. Gaia, Portugal 4 Hospital Santa Maria, Lisboa, 
Portugal 5 Hospital Pulido Valente, Lisboa, Portugal 6 Hospital S. 
João, Porto, Portugal 7 Hospital S. Marcos, Braga, Portugal 8 Hospital 
Garcia Orta, Almada, Portugal 
On behalf of the Portuguese Lung Cancer Study Group 
Background: Unitl 2004, docetaxel in monotherapy was the standard 
for second-line treatment of non-small cell lung cancer (NSCLC). 
Pemetrexed (P), an multi-target antifolate, with vitamin supplementa-
tion, has shown similar activity in this setting with a better adverse 
event proﬁle (Hanna N et al, J Clin Oncol 2004;22:1589-1597). In 
Portugal, it was introduced in October of 2004 for second-line mono-
therapy. We have carried out a retrospective analysis of patients who 
received P for second-line NSCLC in Portugal from October 2004 to 
December 2006.
Methods: Data were collected retrospectively from the records of 
patients (pts) enrolled in centers participating in the Portuguese Lung 
Cancer Study Group (GECP). The pts had locally advanced or meta-
static NSCLC and failed ﬁrst-line chemotherapy. They received P (500 
mg/m2 on a three-weekly schedule with vitamin supplementation). 
Objective response (OR; complete [CR] or partial [PR] response) was 
evaluated using RECIST and safety assessed using serious or non-seri-
ous adverse events (SAEs/AEs).
Results: By December 2006, 19 GECP centers had enrolled 244 
pts who had received P for ≥1 cycle, and were considered evaluable 
for both objective response and safety. Demography: male/female, 
175/69; median age, 57.0 years (range 20-81); smoking status, y/ex/n, 
116/57/71 adenocarcinoma/squamous-cell carcinoma/other histology, 
141/72/31; prior chemotherapy, platin plus gemcitabine/paclitaxel/
vinorelbine/docetaxel, 152/37/30/19; mean number of cycles in 1st 
line, 4.8 (range 1-8); disease control (OR + stable disease [SD]) was 
observed in 170 (61.0%) pts: 7 CR, 79 PR and 84 SD; mean time to 
progression (TTP) 8.07 months. P mean number of cycles in 2nd line, 
4.1 (range1-15); disease control in 209 evaluable pts was observed in 
116 (55.5%): 2 CR, 45 PR and 69 SD; mean TTP 4.70 months. The 
majority of AEs were grade 3 anemia (15 pts) and neutropenia (18 pts). 
The mean overall survival was 17.27 months.
Conclusions: Our retrospective analysis has observed a similar disease 
control rate with P in 2nd line (55.5%), and TTP (4.7 months) in our 
current unselected population to that published in the literature. P is an 
option for second-line NSCLC with a good tolerability.
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A retrospective study between docetaxel and pemetrexed for second 
line treatment of non-small cell lung cancer in a single institution
Araujo, António M.; Rego, Sónia; Azevedo, Isabel; Soares, Marta 
Portuguese Institute of Oncology - Porto Centre, Porto, Portugal
Background: Docetaxel (D) and Pemetrexed (P) are two options for 
the second-line treatment of non small-cell lung cancer (NSCLC), 
with similar response rates and overall survivals but different toxicity 
(Hanna N et al, J Clin Oncol 2004;22:1589-1597). P was introduced 
in Portugal in October 2004. The authors carried out a retrospective 
study of patients (pts) diagnosed with NSCLC treated in 2nd line with 
D or P at Portuguese Institute of Oncology - Porto Centre (IPO-Porto), 
Portugal.
Methods: We made a retrospective review of the pt clinical ﬁles with 
NSCLC treated in second-line with D or P between December 2003 
and December 2006 at IPO-Porto. The primary objective was the 
evaluation of safety assessed using serious or non-serious adverse 
events. Secondary objectives were to assess time to progression (TTP) 
and overall survival (OS) between the two drugs on that unselected 
population.
Results: Of 96 evaluated pts who received 2nd line chemotherapy 
(CT), 78% were male. Median age at diagnosis was 63 years (range: 
29-81); 38% were adenocarcinomas, 58% squamous cell carcinoma 
and 4% were large cell carcinomas; 99% had a performance status 
ECOG 0. At diagnosis, 50% had metastasis in at least one site. All pts 
received platin ﬁrst line based CT. At 2nd line treatment, 77 (80%) re-
ceived D and 19 (20%) P. Mean number of cycles received was 5.6 for 
D and 4.3 for P. The sum of grade III toxicities were observed on 27 pts 
on D and 7 on P, and grade IV toxicities were observed on 10 pts on D 
and none on P. Incidence of grade III anaemia was 12% on D and 11% 
